24 May 2013
Keywords: s-p, tra, meets, ph, ii, study, endpoints
Article | 23 March 2009
US drug major Schering-Plough says that SCH 530348, its novel oral thrombin receptor antagonist, met the primary endpoints of safety and
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 March 2009
23 May 2013
© 2013 thepharmaletter.com